Abstract
Comorbidity and relative dose intensity (RDI) have been associated with survival in diffuse large B-cell lymphoma (DLBCL) patients, but both relationships remain unaddressed in the same patients. A retrospective review of consecutive DLBCL patients treated from January 2010 to October 2018 was performed. Data for the clinical characteristics of the patients, including the Charlson Comorbidity Index (CCI) and RDI, on their outcomes were evaluated. A total of 211 patients with a median age of 72 years (range 19-90 years) were analyzed. CCI ≥ 2 was associated with poor event-free survival (EFS) and overall survival (OS). RDI < 70% was associated with worse EFS and OS. A multivariate analysis revealed that RDI < 70% was only a poor risk factor for the reduction of OS in elderly DLBCL patients (65 years <) and independent from the presence of CCI. The relationship between CCI and RDI in elderly patients was analyzed in four groups, based on CCI ≥ 2 or less and RDI ≥ 70% or less. The group with CCI ≥ 2 and RDI < 70% had a poorer OS and EFS, as compared to the other three groups. The group with CCI < 2 and RDI ≥ 70% had a superior OS but an identical EFS, as compared to the two groups with CCI < 2 and RDI < 70% and CCI ≥ 2 and RDI ≥ 7...Continue Reading
References
May 27, 2005·British Journal of Haematology·Maryska L G Janssen-HeijnenJan Willem W Coebergh
Aug 20, 2009·Journal of Experimental & Clinical Cancer Research : CR·Yoshiki TeradaMasayuki Hino
Apr 24, 2010·Annals of Hematology·Tsuneaki HirakawaKazuo Dan
Oct 30, 2010·CA: a Cancer Journal for Clinicians·Christopher R FlowersJulie M Vose
Apr 13, 2011·The Lancet Oncology·Frédéric PeyradeUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators
Apr 3, 2012·British Journal of Haematology·Paul A Fields, David C Linch
Nov 23, 2013·Blood·Zheng ZhouJane N Winter
Apr 24, 2014·British Journal of Haematology·Andre WieringaEric N van Roon
Aug 1, 2015·British Journal of Haematology·Toby A EyreChris S Hatton
Oct 16, 2015·[Rinshō ketsueki] The Japanese journal of clinical hematology·Yoshinobu Kanda
May 12, 2016·Annals of Hematology·Hee Sang HwangJooryung Huh
Sep 20, 2016·Annals of Hematology·Yotaro OchiTakayuki Ishikawa
Oct 1, 2016·Leukemia & Lymphoma·Yusuke KanemasaYoshiharu Maeda
Oct 12, 2016·Leukemia & Lymphoma·Katsushi TajimaUNKNOWN Tohoku Hematology Forum
Oct 21, 2016·British Journal of Cancer·Katharina T ProchazkaMartin Pichler
Jan 21, 2017·British Journal of Haematology·Carlos MontalbánUNKNOWN GELTAMO-IPI Project Investigators
Apr 15, 2017·The Oncologist·Katsuhiro MiuraMasatoshi Kanno
Jun 15, 2017·American Journal of Hematology·Caner SayginDeepa Jagadeesh
Aug 23, 2017·Leukemia & Lymphoma·Liat VidalAnat Gafter-Gvili
Feb 25, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tarec Christoffer El-GalalyDiego Villa
Oct 29, 2018·Journal of Internal Medicine·T WästerlidS Eloranta
Feb 28, 2019·Journal of Internal Medicine·T A EyreC S R Hatton
Citations
Mar 20, 2021·International Journal of Hematology·Masataka IseMineo Kurokawa
May 8, 2021·Blood Advances·Edward J BataillardTarec Christoffer El-Galaly
Jun 12, 2021·Expert Review of Anticancer Therapy·Michelle ShayneGary H Lyman
Jul 31, 2021·The Oncologist·P Connor JohnsonAreej El-Jawahri